Di Bacco, A., Bahlis, N. J., Munshi, N. C., Avet‐Loiseau, H., Masszi, T., Viterbo, L., . . . Moreau, P. (2020). c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma. European journal of haematology, 105(1), 35-46. https://doi.org/10.1111/ejh.13405
Chicago-Zitierstil (17. Ausg.)Di Bacco, Alessandra, et al. "C‐MYC Expression and Maturity Phenotypes Are Associated with Outcome Benefit from Addition of Ixazomib to Lenalidomide‐dexamethasone in Myeloma." European Journal of Haematology 105, no. 1 (2020): 35-46. https://doi.org/10.1111/ejh.13405.
MLA-Zitierstil (9. Ausg.)Di Bacco, Alessandra, et al. "C‐MYC Expression and Maturity Phenotypes Are Associated with Outcome Benefit from Addition of Ixazomib to Lenalidomide‐dexamethasone in Myeloma." European Journal of Haematology, vol. 105, no. 1, 2020, pp. 35-46, https://doi.org/10.1111/ejh.13405.